UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q


☑			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~January~~April 3130, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from to

Commission File Number 1-14959

BRADY CORPORATION

(Exact name of registrant as specified in its charter)


Wisconsin						39-0178960
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

6555 West Good Hope Road

Milwaukee, Wisconsin 53223

(Address of principal executive offices and zip code)

(414) 358-6600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Class A Nonvoting Common Stock, par value $0.01 per share	BRC	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☑

Accelerated filer

☐

Emerging growth company

☐

Non-accelerated filer

☐

Smaller reporting company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of ~~February~~May 1914, 2025, there were 4443,~~241~~776,~~601~~968 outstanding shares of Class A Nonvoting Common Stock and 3,538,628 shares of Class B Voting Common Stock. The Class B Voting Common Stock, all of which is held by affiliates of the Registrant, is the only voting stock.

Table of Contents

INDEX

			Page
PART I. Financial Information			3
Item 1. Financial Statements (Unaudited)			3
Condensed Consolidated Balance Sheets			3
Condensed Consolidated Statements of Income			4
Condensed Consolidated Statements of Comprehensive Income			5
Condensed Consolidated Statements of Stockholders' Equity			6
Condensed Consolidated Statements of Cash Flows			8
Notes to Condensed Consolidated Financial Statements			9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			18
Item 3. Quantitative and Qualitative Disclosures About Market Risk			2425
Item 4. Controls and Procedures			25
PART II. Other Information			26
Item 1. Legal Proceedings			26
Item 1A. Risk Factors			26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			26
Item 5. Other Information			26
Item 6. Exhibits			27
Signatures			28

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BRADY CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	~~138~~152,~~452~~154	$	250,118
Accounts receivable, net of allowance for credit losses of $9,227 and $6,749, respectively	201,973		185,486
Accounts receivable, net of allowance for credit losses of $8,967 and $6,749, respectively	224,358		185,486
Inventories	~~181~~189,~~810~~991		152,729
Prepaid expenses and other current assets	1415,~~080~~399		11,382
Total current assets	~~536~~581,~~315~~902		599,715
Property, plant and equipment—net	~~199~~219,~~075~~082		195,758
Goodwill	~~661~~682,~~288~~554		589,611
Other intangible assets	~~108~~111,~~456~~685		51,839
Deferred income taxes	1620,~~587~~583		15,596
Operating lease assets	4258,~~135~~118		38,504
Other assets	24,~~844~~191		24,546
Total	$	1,~~588~~698,~~700~~115	$	1,515,569
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	9099,~~968~~754	$	84,691
Accrued compensation and benefits	6987,~~551~~506		77,954
Taxes, other than income taxes	1819,~~794~~711		14,061
Accrued income taxes	42,~~416~~976		7,424
Current operating lease liabilities	1415,~~922~~030		13,382
Other current liabilities	8386,~~699~~809		67,170
Total current liabilities	~~282~~311,~~350~~786		264,682
Long-term debt	87102,~~687~~819		90,935
Long-term operating lease liabilities	2743,~~546~~772		25,342
Other liabilities	7072,~~649~~185		67,952
Total liabilities	~~468~~530,~~232~~562		448,911
Stockholders’ equity:
Class A nonvoting common stock—Issued 51,261,487 shares, and outstanding 44,241,601 and 44,042,462 shares, respectively	513		513
Class A nonvoting common stock—Issued 51,261,487 shares, and outstanding 43,774,580 and 44,042,462 shares, respectively	513		513
Class B voting common stock—Issued and outstanding, 3,538,628 shares	35		35
Additional paid-in capital	~~356~~357,~~531~~545		353,654
Retained earnings	1,~~238~~279,~~275~~168		1,174,025
Treasury stock—7,019,886 and 7,219,025 shares, respectively, of Class A nonvoting common stock, at cost	(343,059)		(351,947)
Treasury stock—7,486,907 and 7,219,025 shares, respectively, of Class A nonvoting common stock, at cost	(375,974)		(351,947)
Accumulated other comprehensive loss	(~~131~~93,~~827~~734)		(109,622)
Total stockholders’ equity	1,~~120~~167,~~468~~553		1,066,658
Total	$	1,~~588~~698,~~700~~115	$	1,515,569

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

BRADY CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Dollars in Thousands, Except Per Share Amounts, Unaudited)

Three months ended January 31,

Six months ended January 31,

Three months ended April 30,

Nine months ended April 30,

2025

2024

2025

2024

Net sales

~~356~~382,~~675~~590

~~322~~343,~~624~~384

~~733~~1,~~740~~116,330

~~654~~997,~~607~~991

Cost of goods sold

~~180~~187,~~832~~531

~~160~~166,~~541~~357

~~368~~555,~~208~~739

~~320~~487,~~805~~162

Gross margin

~~175~~195,~~843~~059

~~162~~177,~~083~~027

~~365~~560,~~532~~591

~~333~~510,~~802~~829

Operating expenses:

Research and development

1819,~~723~~191

1617,~~832~~681

3756,~~644~~835

3250,~~534~~215

Selling, general and administrative

~~105~~108,~~886~~678

9195,~~325~~803

~~217~~326,~~732~~410

~~187~~283,~~612~~415

Total operating expenses

~~124~~127,~~609~~869

~~108~~113,~~157~~484

~~255~~383,~~376~~245

~~220~~333,~~146~~630

Operating income

5167,~~234~~190

5363,~~926~~543

~~110~~177,~~156~~346

~~113~~177,~~656~~199

Other income (expense):

Other (expense) income:

Investment and other income

2,125

2,684

3,359

3,122

Investment and other (expense) income

(509)

1,596

2,850

4,718

Interest expense

(~~1,312~~936)

(~~790~~728)

(23,~~668~~604)

(12,~~556~~284)

Income before income taxes

5265,~~047~~745

5564,~~820~~411

~~110~~176,~~847~~592

~~115~~179,~~222~~633

Income tax expense

1113,~~713~~482

1213,~~192~~521

2337,~~730~~212

2437,~~353~~874

Net income

4052,~~334~~263

4350,~~628~~890

87139,~~117~~380

90141,~~869~~759

Net income per Class A Nonvoting Common Share:

Basic

01.8410

01.9006

12.8292

12.8894

Diluted

01.8309

01.9005

12.8189

12.8691

Net income per Class B Voting Common Share:

Basic

01.8410

01.9006

12.8190

12.8692

Diluted

01.8309

01.9005

12.7988

12.8590

Weighted average common shares outstanding:

Basic

47,~~851~~644

48,~~374~~004

47,~~792~~743

48,~~440~~294

Diluted

48,~~306~~066

48,~~725~~386

48,~~261~~196

48,~~768~~640

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

BRADY CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Dollars in Thousands, Unaudited)

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Net income	$	4052,~~334~~263	$	4350,~~628~~890	$	87139,~~117~~380	$	90141,~~869~~759
Other comprehensive (loss) income:
Other comprehensive income (loss):
Foreign currency translation adjustments	~~(21~~38,~~180)~~161		14(6,~~591~~537)		~~(21~~16,~~259)~~902		(512,~~773~~310)
Cash flow hedges:
Net gain (loss) recognized in other comprehensive (loss) income	935		1,083		(403)		789
Net (loss) gain recognized in other comprehensive income (loss)	(423)		447		(826)		1,236
Reclassification adjustment for losses (gains) included in net income	~~463~~210		(~~254~~173)		~~(1)~~209		(1,~~539~~712)
	1,398		829		(404)		(750)
	(213)		274		(617)		(476)
Pension and other post-retirement benefits actuarial gain amortization	(~~151~~152)		(~~151~~152)		(~~302~~454)		(~~302~~454)
Other comprehensive (loss) income, before tax	(19,933)		15,269		(21,965)		(6,825)
Other comprehensive income (loss), before tax	37,796		(6,415)		15,831		(13,240)
Income tax (expense) benefit related to items of other comprehensive (loss) income	(292)		73		(240)		(55)
Income tax benefit (expense) related to items of other comprehensive income (loss)	297		(51)		57		(106)
Other comprehensive (loss) income, net of tax	(20,225)		15,342		(22,205)		(6,880)
Other comprehensive income (loss), net of tax	38,093		(6,466)		15,888		(13,346)
Comprehensive income	$	2090,~~109~~356	$	5844,~~970~~424	$	64155,~~912~~268	$	83128,~~989~~413

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

BRADY CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Dollars in Thousands, Unaudited)

	Three months ended January 31, 2025
	Three months ended April 30, 2025
	Common Stock		Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balances at October 31, 2024	$	548	$	354,592	$	1,209,406	$	(344,012)	$	(111,602)	$	1,108,932
Balances at January 31, 2025	$	548	$	356,531	$	1,238,275	$	(343,059)	$	(131,827)	$	1,120,468
Net income	—		—		4052,~~334~~263		—		—		4052,~~334~~263
Other comprehensive loss, net of tax	—		—		—		—		(20,225)		(20,225)
Other comprehensive income, net of tax	—		—		—		—		38,093		38,093
Issuance of shares of Class A Common Stock under stock plan	—		(~~241~~755)		—		~~953~~415		—		~~712~~(340)
Stock-based compensation expense	—		21,~~180~~769		—		—		—		21,~~180~~769
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(33,330)		—		(33,330)
Cash dividends on Common Stock:
Class A — $0.2400 per share	—		—		(10,~~616~~521)		—		—		(10,~~616~~521)
Class B — $0.2400 per share	—		—		(849)		—		—		(849)
Balances at January 31, 2025	$	548	$	356,531	$	1,238,275	$	(343,059)	$	(131,827)	$	1,120,468
Balances at April 30, 2025	$	548	$	357,545	$	1,279,168	$	(375,974)	$	(93,734)	$	1,167,553

	Six months ended January 31, 2025
	Nine months ended April 30, 2025
	Common Stock		Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balances at July 31, 2024	$	548	$	353,654	$	1,174,025	$	(351,947)	$	(109,622)	$	1,066,658
Net income	—		—		87139,~~117~~380		—		—		87139,~~117~~380
Other comprehensive loss, net of tax	—		—		—		—		(22,205)		(22,205)
Other comprehensive income, net of tax	—		—		—		—		15,888		15,888
Issuance of shares of Class A Common Stock under stock plan	—		(56,~~306~~061)		—		89,~~888~~303		—		3,~~582~~242
Tax benefit and withholdings from deferred compensation distributions	—		190		—		—		—		190
Stock-based compensation expense	—		79,~~993~~762		—		—		—		79,~~993~~762
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(33,330)		—		(33,330)
Cash dividends on Common Stock:
Class A — $0.4800 per share	—		—		(21,228)		—		—		(21,228)
Class A — $0.7200 per share	—		—		(31,749)		—		—		(31,749)
Class B — $0.4634 per share	—		—		(1,639)		—		—		(1,639)
Class B — $0.7034 per share	—		—		(2,488)		—		—		(2,488)
Balances at January 31, 2025	$	548	$	356,531	$	1,238,275	$	(343,059)	$	(131,827)	$	1,120,468
Balances at April 30, 2025	$	548	$	357,545	$	1,279,168	$	(375,974)	$	(93,734)	$	1,167,553

	Three months ended January 31, 2024
	Common Stock		Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balances at October 31, 2023	$	548	$	352,421	$	1,057,773	$	(300,467)	$	(115,283)	$	994,992
Net income	—		—		43,628		—		—		43,628
Other comprehensive income, net of tax	—		—		—		—		15,342		15,342
Issuance of shares of Class A Common Stock under stock plan	—		273		—		2,466		—		2,739
Stock-based compensation expense	—		1,100		—		—		—		1,100
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(7,713)		—		(7,713)
Cash dividends on Common Stock:
Class A — $0.2350 per share	—		—		(10,525)		—		—		(10,525)
Class B — $0.2350 per share	—		—		(831)		—		—		(831)
Balances at January 31, 2024	$	548	$	353,794	$	1,090,045	$	(305,714)	$	(99,941)	$	1,038,732

Table of Contents

	Six months ended January 31, 2024
	Three months ended April 30, 2024
	Common Stock		Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balances at July 31, 2023	$	548	$	351,771	$	1,021,870	$	(290,209)	$	(93,061)	$	990,919
Net income	—		—		90,869		—		—		90,869
Other comprehensive loss, net of tax	—		—		—		—		(6,880)		(6,880)
Issuance of shares of Class A Common Stock under stock plan	—		(3,389)		—		6,393		—		3,004
Tax benefit and withholdings from deferred compensation distributions	—		149		—		—		—		149
Stock-based compensation expense	—		5,263		—		—		—		5,263
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(21,898)		—		(21,898)
Cash dividends on Common Stock:
Class A — $0.4700 per share	—		—		(21,090)		—		—		(21,090)
Class B — $0.4534 per share	—		—		(1,604)		—		—		(1,604)
Balances at January 31, 2024	$	548	$	353,794	$	1,090,045	$	(305,714)	$	(99,941)	$	1,038,732
Net income	—		—		50,890		—		—		50,890
Other comprehensive loss, net of tax	—		—		—		—		(6,466)		(6,466)
Issuance of shares of Class A Common Stock under stock plan	—		(521)		—		436		—		(85)
Stock-based compensation expense	—		1,159		—		—		—		1,159
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(50,932)		—		(50,932)
Cash dividends on Common Stock:
Class A — $0.2350 per share	—		—		(10,364)		—		—		(10,364)
Class B — $0.2350 per share	—		—		(832)		—		—		(832)
Balances at April 30, 2024	$	548	$	354,432	$	1,129,739	$	(356,210)	$	(106,407)	$	1,022,102


	Nine months ended April 30, 2024
	Common Stock		Additional Paid-In Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
Balances at July 31, 2023	$	548	$	351,771	$	1,021,870	$	(290,209)	$	(93,061)	$	990,919
Net income	—		—		141,759		—		—		141,759
Other comprehensive loss, net of tax	—		—		—		—		(13,346)		(13,346)
Issuance of shares of Class A Common Stock under stock plan	—		(3,910)		—		6,829		—		2,919
Tax benefit and withholdings from deferred compensation distributions	—		149		—		—		—		149
Stock-based compensation expense	—		6,422		—		—		—		6,422
Repurchase of shares of Class A Common Stock, including excise taxes	—		—		—		(72,830)		—		(72,830)
Cash dividends on Common Stock:
Class A — $0.7050 per share	—		—		(31,454)		—		—		(31,454)
Class B — $0.6884 per share	—		—		(2,436)		—		—		(2,436)
Balances at April 30, 2024	$	548	$	354,432	$	1,129,739	$	(356,210)	$	(106,407)	$	1,022,102

Table of Contents

BRADY CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands, Unaudited)

	Six months ended January 31,
	Nine months ended April 30,
	2025		2024
Operating activities:
Net income	$	87139,~~117~~380	$	90141,~~869~~759
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2030,~~096~~279		1522,~~008~~406
Stock-based compensation expense	79,~~993~~762		56,~~263~~422
Deferred income taxes	(36,~~076~~038)		(36,~~640~~902)
Other	~~231~~(181)		~~947~~1,358
Changes in operating assets and liabilities:
Accounts receivable	(6,~~605~~869)		(515,~~030~~915)
Inventories	(8,~~384~~209)		1020,~~078~~861
Prepaid expenses and other assets	(23,~~571~~754)		(1,~~187~~849)
Accounts payable and accrued liabilities	(4126,~~650~~415)		(97,~~754)~~347
Income taxes	(35,~~361~~081)		(4,~~203~~393)
Net cash provided by operating activities	63122,~~000~~874		98171,~~351~~094
Investing activities:
Purchases of property, plant and equipment	(1418,~~423~~685)		(6069,~~832~~157)
Acquisition of businesses, net of cash acquired	(~~137~~147,~~348~~248)		—
Other	53854		—(1,174)
Net cash used in investing activities	(~~151~~165,~~718~~079)		(6070,~~832~~331)
Financing activities:
Payment of dividends	(2234,~~867~~237)		(2233,~~694~~890)
Proceeds from exercise of stock options	5,~~712~~759		5,~~366~~583
Payments for employee taxes withheld from stock-based awards	(2,~~130~~518)		(2,~~362~~664)
Purchase of treasury stock	—(33,155)		(2172,~~797~~225)
Proceeds from borrowing on credit agreement	~~159~~206,~~373~~249		69111,~~145~~790
Repayment of borrowing on credit agreement	(~~162~~194,~~621~~365)		(7097,~~771~~732)
Other	190		149
Net cash used in financing activities	(2252,~~343~~077)		(4288,~~964~~989)
Effect of exchange rate changes on cash and cash equivalents	(~~605~~3,682)		(2,~~227~~848)
Net decrease in cash and cash equivalents	(111,666)		(7,672)
Net (decrease) increase in cash and cash equivalents	(97,964)		8,926
Cash and cash equivalents, beginning of period	250,118		151,532
Cash and cash equivalents, end of period	$	~~138~~152,~~452~~154	$	~~143~~160,~~860~~458

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

BRADY CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~Six~~Nine Months Ended ~~January~~April 3130, 2025

(Unaudited)

(In thousands, except share and per share amounts)

NOTE A — Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by Brady Corporation and subsidiaries (the “Company,” “Brady,” “we,” or “our”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the Company, the foregoing statements contain all adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial position of the Company as of ~~January~~April 3130, 2025 and July 31, 2024, its results of operations and comprehensive income for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, and cash flows for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024. The condensed consolidated balance sheet as of July 31, 2024 has been derived from the audited consolidated financial statements as of that date. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts therein. Due to the inherent uncertainty involved in making estimates, actual results in future periods may differ from the estimates.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to rules and regulations of the Securities and Exchange Commission. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statement presentation. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2024.

NOTE B — New Accounting Pronouncements

Standards not yet adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The guidance requires expanded interim and annual disclosures of segment information including the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within segment profit and loss. The guidance is effective for the Company's fiscal 2025 Form 10-K and interim periods thereafter. The Company is currently assessing its segment information disclosures in connection with the adoption of ASU 2023-07.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance requires expanded annual disclosures including the standardization and disaggregation of income tax rate reconciliation categories and the amount of income taxes paid by jurisdiction. The guidance is effective for the Company’s fiscal 2026 Form 10-K. The Company is currently assessing its income tax disclosures in connection with the adoption of ASU 2023-09.

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” The guidance requires expanded interim and annual disclosures of expense information including the amounts of inventory purchases, employee compensation, depreciation, amortization, and depletion within commonly presented expense captions during the period. The guidance is effective for the Company's fiscal 2028 Form 10-K and interim periods thereafter. The Company is currently evaluating the ASU to determine its impact on the Company's disclosures.

Table of Contents

NOTE C — Additional Balance Sheet Information

Inventories

Inventories consisted of the following as of ~~January~~April 3130, 2025 and July 31, 2024:

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
Finished products	$	~~102~~104,~~614~~559	$	89,430
Work-in-process	2729,~~418~~332		24,601
Raw materials and supplies	5156,~~778~~100		38,698
Total inventories	$	~~181~~189,~~810~~991	$	152,729

Property, plant and equipment

Property, plant and equipment is presented net of accumulated depreciation in the amount of $~~307~~309,~~266~~349 and $304,199 as of ~~January~~April 3130, 2025 and July 31, 2024, respectively.

NOTE D — Other Intangible Assets

Other intangible assets as of ~~January~~April 3130, 2025 and July 31, 2024 consisted of the following:

	January 31, 2025							July 31, 2024
	April 30, 2025							July 31, 2024
	Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value		Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value
Amortized other intangible assets:
Tradenames	2	$	~~831~~911	$	(~~208~~342)	$	~~623~~569	3	$	600	$	(600)	$	—
Customer relationships	8	~~119~~126,~~165~~148		(3034,~~026~~778)		8991,~~139~~370		9	64,430		(23,279)		41,151
Technology	5	1921,~~273~~500		(89,~~091~~411)		1112,~~182~~089		5	9,300		(6,182)		3,118
Unamortized other intangible assets:
Tradenames	N/A	7,~~512~~657		—		7,~~512~~657		N/A	7,570		—		7,570
Total		$	~~146~~156,~~781~~216	$	(3844,~~325~~531)	$	~~108~~111,~~456~~685		$	81,900	$	(30,061)	$	51,839

The change in the gross carrying amount of other intangible assets as of ~~January~~April 3130, 2025 compared to July 31, 2024 was primarily due to the acquisitions of Gravotech Holding (“Gravotech”), ~~and~~ American Barcode and RFID Incorporated (“AB&R”), and the Microfluidic Solutions business unit of Funai Electric Co., Ltd. (“Microfluidic Solutions”) completed during the ~~six~~nine months ended ~~January~~April 3130, 2025 and to a lesser extent, the effect of currency fluctuations. Refer to Note N, “Acquisitions,” for additional information on intangible assets acquired.

Amortization expense on intangible assets was $4,~~671~~754 and $2,~~364~~365 for the three months ended ~~January~~April 3130, 2025 and 2024, respectively, and $914,~~384~~138 and $47,~~719~~084 for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively.

NOTE E — Leases

The Company leases certain manufacturing facilities, warehouse and office spaces, and vehicles accounted for as operating leases. Lease terms typically range from one year to ten years. As of ~~January~~April 3130, 2025, the Company did not have any finance leases.

Operating lease expense was $4,~~539~~714 and $3,~~804~~688 for the three months ended ~~January~~April 3130, 2025 and 2024, respectively, and $913,~~274~~988 and $711,~~869~~557 for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively, which was recognized in either “Cost of goods sold” or “Selling, general and administrative” expenses in the condensed consolidated statements of income, based on the nature of the lease. Short-term lease expense, variable lease expenses, and sublease income were immaterial to the condensed consolidated statements of income for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024.

Table of Contents

Supplemental cash flow information related to the Company's operating leases for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024 was as follows:

	Six months ended January 31,
	Nine months ended April 30,
	2025		2024
Operating cash outflows from operating leases	$	913,~~157~~780	$	812,~~585~~441
Operating lease assets obtained in exchange for new operating lease liabilities (1)	1230,~~749~~964		28,~~551~~903

(1) Includes new leases and remeasurements or modifications of existing leases.

NOTE F — Accumulated Other Comprehensive Loss

Other comprehensive income (loss) consists of foreign currency translation adjustments, which includes net investment hedges and long-term intercompany loan translation adjustments, unrealized gains and losses from cash flow hedges, and the unamortized gain on post-retirement plans, net of their related tax effects.

The following table illustrates the changes in the balances of each component of accumulated other comprehensive loss, net of tax, for the ~~six~~nine months ended ~~January~~April 3130, 2025:

	Unrealized loss on cash flow hedges		Unamortized gain on post-retirement plans		Foreign currency translation adjustments		Accumulated other comprehensive loss
Beginning balance, July 31, 2024	$	(149)	$	462	$	(109,935)	$	(109,622)
Other comprehensive loss before reclassification	(643)		—		(21,259)		(21,902)
Other comprehensive (loss) income before reclassification	(716)		—		16,902		16,186
Amounts reclassified from accumulated other comprehensive loss	~~(1)~~156		(~~302~~454)		—		(~~303~~298)
Ending balance, January 31, 2025	$	(793)	$	160	$	(131,194)	$	(131,827)
Ending balance, April 30, 2025	$	(709)	$	8	$	(93,033)	$	(93,734)

The ~~increase~~decrease in accumulated other comprehensive loss as of ~~January~~April 3130, 2025 compared to July 31, 2024 was primarily due to the ~~appreciation~~depreciation of the U.S. dollar against certain other currencies during the ~~six~~nine-month period.

The changes in accumulated other comprehensive loss by component, net of tax, for the ~~six~~nine months ended ~~January~~April 3130, 2024 were as follows:

	Unrealized gain on cash flow hedges		Unamortized gain on post-retirement plans		Foreign currency translation adjustments		Accumulated other comprehensive loss
Beginning balance, July 31, 2023	$	1,641	$	756	$	(95,458)	$	(93,061)
Other comprehensive income (loss) before reclassification	~~350~~702		—		(512,~~773~~310)		(511,~~423~~608)
Amounts reclassified from accumulated other comprehensive loss	(1,~~155~~284)		(~~302~~454)		—		(1,~~457~~738)
Ending balance, January 31, 2024	$	836	$	454	$	(101,231)	$	(99,941)
Ending balance, April 30, 2024	$	1,059	$	302	$	(107,768)	$	(106,407)

The increase in accumulated other comprehensive loss as of ~~January~~April 3130, 2024 compared to July 31, 2023 was primarily due to the appreciation of the U.S. dollar against certain other currencies during the ~~six~~nine-month period.

Of the amounts reclassified from accumulated other comprehensive loss during the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, unrealized (losses) gains on cash flow hedges were reclassified to “Cost of goods sold” and unamortized gains on post-retirement plans were reclassified into “Investment and other (expense) income” on the condensed consolidated statements of income.

The following table illustrates the income tax benefit (expense) ~~benefit~~ on the components of other comprehensive income (loss) for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Income tax (expense) benefit related to items of other comprehensive loss:
Income tax benefit (expense) related to items of other comprehensive loss:
Cash flow hedges	$	~~(292)~~297	$	73(51)	$	~~(240)~~57	$	(55106)

Table of Contents

NOTE G — Revenue Recognition

The Company recognizes revenue when control of the product or service transfers to the customer at an amount that represents the consideration expected to be received in exchange for those products and services. The Company’s revenues are primarily from the sale of identification solutions and workplace safety products that are shipped and billed to customers. All revenue is from contracts with customers and is included in “Net sales” on the condensed consolidated statements of income. See Note H, “Segment Information,” for the Company’s disaggregated revenue disclosure.

The Company offers extended warranty coverage that is included in the sales price of certain products, which it accounts for as service warranties. The Company accounts for the deferred revenue associated with extended service warranties as a contract liability. The balance of contract liabilities associated with service warranty performance obligations was $2,~~963~~986 and $2,947 as of ~~January~~April 3130, 2025 and July 31, 2024, respectively. The current portion and non-current portion of contract liabilities are included in “Other current liabilities” and “Other liabilities,” respectively, on the condensed consolidated balance sheets. The Company recognized revenue of $~~341~~343 and $~~321~~325 during the three months ended ~~January~~April 3130, 2025 and 2024, respectively, and $~~678~~1,021 and $~~635~~960 during the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively, that was included in the contract liability balance at the beginning of the respective period from the amortization of extended service warranties. Of the contract liability balance outstanding at ~~January~~April 3130, 2025, the Company expects to recognize 2212% by the end of fiscal 2025, an additional 3538% by the end of fiscal 2026, and the remaining balance thereafter.

NOTE H — Segment Information

The Company is organized and managed within two regions: Americas & Asia and Europe & Australia, which are the reportable segments.

The following is a summary of net sales by segment and geographic region for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024:

Three months ended January 31,

Six months ended January 31,

Three months ended April 30,

Nine months ended April 30,

2025

2024

2025

2024

Net sales:

Americas & Asia

Americas

~~202~~219,~~547~~913

~~185~~200,~~976~~602

~~416~~636,~~580~~493

~~382~~582,~~262~~864

Asia

3133,~~299~~739

2524,~~667~~164

6296,~~694~~433

5175,~~007~~171

Total

~~233~~253,~~846~~652

~~211~~224,~~643~~766

~~479~~732,~~274~~926

~~433~~658,~~269~~035

Europe & Australia

Europe

~~110~~115,~~477~~715

98104,~~371~~925

~~226~~342,~~630~~345

~~194~~299,~~704~~629

Australia

1213,~~352~~223

1213,~~610~~693

2741,~~836~~059

2640,~~634~~327

Total

~~122~~128,~~829~~938

~~110~~118,~~981~~618

~~254~~383,~~466~~404

~~221~~339,~~338~~956

Total Company

~~356~~382,~~675~~590

~~322~~343,~~624~~384

~~733~~1,~~740~~116,330

~~654~~997,~~607~~991

The following is a summary of segment profit for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024:

Three months ended January 31,

Six months ended January 31,

Three months ended April 30,

Nine months ended April 30,

2025

2024

2025

2024

Segment profit:

Americas & Asia

4557,~~986~~164

4349,~~895~~697

~~100~~158,~~886~~148

93143,~~792~~489

Europe & Australia

1117,~~378~~478

1519,~~054~~537

2441,~~492~~872

3151,~~798~~335

Total profit from reportable segments

5774,~~364~~642

5869,~~949~~234

~~125~~200,~~378~~020

~~125~~194,~~590~~824

Table of Contents

Total profit from reportable segments is a measure of operating income that excludes administrative costs related to corporate functions that are otherwise included in the Company's operating income. The following is a reconciliation of total profit from reportable segments to income before income taxes for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Total profit from reportable segments	$	5774,~~364~~642	$	5869,~~949~~234	$	~~125~~200,~~378~~020	$	~~125~~194,~~590~~824
Unallocated amounts:
Administrative costs	(67,~~130~~452)		(5,~~023~~691)		(1522,~~222~~674)		(1117,~~934~~625)
Investment and other income	2,125		2,684		3,359		3,122
Investment and other (expense) income	(509)		1,596		2,850		4,718
Interest expense	(~~1,312~~936)		(~~790~~728)		(23,~~668~~604)		(12,~~556~~284)
Income before income taxes	$	5265,~~047~~745	$	5564,~~820~~411	$	~~110~~176,~~847~~592	$	~~115~~179,~~222~~633

NOTE I — Net Income per Common Share

Reconciliations of the numerator and denominator of the basic and diluted per share computations for the Company’s Class A and Class B common stock are summarized as follows:

	Three months ended January 31,				Six months ended January 31,
	Three months ended April 30,				Nine months ended April 30,
	2025		2024		2025		2024
Numerator (in thousands):
Net income (Numerator for basic and diluted income per Class A Nonvoting Common Share)	$	4052,~~334~~263	$	4350,~~628~~890	$	87139,~~117~~380	$	90141,~~869~~759
Less:
Preferential dividends	—		—		(736)		(748)
Preferential dividends on dilutive stock options	—		—		(8)		(5)
Numerator for basic and diluted income per Class B Voting Common Share	$	4052,~~334~~263	$	4350,~~628~~890	$	86138,~~373~~636	$	90141,~~116~~006
Denominator (in thousands):
Denominator for basic income per share for both Class A and Class B	47,~~851~~644		48,~~374~~004		47,~~792~~743		48,~~440~~294
Plus: Effect of dilutive equity awards	~~455~~422		~~351~~382		~~469~~453		~~328~~346
Denominator for diluted income per share for both Class A and Class B	48,~~306~~066		48,~~725~~386		48,~~261~~196		48,~~768~~640
Net income per Class A Nonvoting Common Share:
Basic	$	01.8410	$	01.9006	$	12.8292	$	12.8894
Diluted	$	01.8309	$	01.9005	$	12.8189	$	12.8691
Net income per Class B Voting Common Share:
Basic	$	01.8410	$	01.9006	$	12.8190	$	12.8692
Diluted	$	01.8309	$	01.9005	$	12.7988	$	12.8590

Potentially dilutive securities attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted earnings per share where the combined exercise price and average unamortized fair value were greater than the average market price of the Company's Class A Nonvoting Common Stock because the effect would have been anti-dilutive. There were no anti-dilutive shares for the three months ended ~~January~~April 3130, 2025. The amount of anti-dilutive shares were 4947,~~562~~409 for the three months ended ~~January~~April 3130, 2024, and 85,~~639~~759 and ~~181~~136,~~674~~919 for the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, respectively.

Table of Contents

NOTE J — Fair Value Measurements

In accordance with fair value accounting guidance, the Company determines fair value based on the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The inputs used to measure fair value are classified into the following hierarchy:

Level 1 — Unadjusted quoted prices in active markets for identical instruments that are accessible as of the reporting date.

Level 2 — Other significant pricing inputs that are either directly or indirectly observable.

Level 3 — Significant unobservable pricing inputs, which result in the use of management's own assumptions.

The following table summarizes the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of ~~January~~April 3130, 2025 and July 31, 2024:

January 31, 2025

July 31, 2024

Fair Value Hierarchy

April 30, 2025

July 31, 2024

Fair Value Hierarchy

Assets:

Deferred compensation plan assets

1918,~~350~~485

20,029

Level 1

Foreign exchange contracts

~~741~~50

137

Level 2

Liabilities:

Foreign exchange contracts

~~1,075~~407

730

Level 2

The following methods and assumptions were used to estimate the fair value of each class of financial instrument:

Deferred compensation plan assets: The Company’s deferred compensation investments consist of investments in mutual funds, which are included in “Other assets” on the condensed consolidated balance sheets. These investments were classified as Level 1 as the shares of these investments trade with sufficient frequency and volume to enable us to obtain pricing information on an ongoing basis.

Foreign exchange contracts: The Company’s foreign exchange contracts were classified as Level 2 as the fair value was based on the present value of the future cash flows using external models that use observable inputs, such as interest rates, yield curves and foreign exchange rates. See Note K, “Derivatives and Hedging Activities,” for additional information.

The fair values of cash and cash equivalents, accounts receivable, accounts payable, and other liabilities approximated carrying values due to their short-term nature.

NOTE K — Derivatives and Hedging Activities

The Company utilizes forward foreign exchange currency contracts to reduce the exchange rate risk of specific foreign currency denominated transactions. These contracts typically require the exchange of a foreign currency for U.S. dollars at a fixed rate on a future date, with maturities of less than 18 months, which qualify as cash flow hedges or net investment hedges under the accounting guidance for derivative instruments and hedging activities. The primary objective of the Company’s foreign currency exchange risk management program is to minimize the impact of currency movements due to transactions in other than the respective subsidiaries’ functional currency and to minimize the impact of currency movements on the Company’s net investment denominated in a currency other than the U.S. dollar. To achieve this objective, the Company hedges a portion of known exposures using forward foreign exchange currency contracts.

Main foreign currency exposures are related to transactions denominated in the British Pound, Euro, Canadian dollar, Australian dollar, Mexican Peso, Chinese Yuan, Malaysian Ringgit and Singapore dollar. Generally, these risk management transactions will involve the use of foreign currency derivatives to minimize the impact of currency movements on non-functional currency transactions.

The U.S. dollar equivalent notional amounts of outstanding forward exchange contracts were as follows:

	January 31, 2025		July 31, 2024
	April 30, 2025		July 31, 2024
Designated as cash flow hedges	$	2914,~~660~~844	$	59,207
Non-designated hedges	4,~~133~~352		4,459
Total foreign exchange contracts	$	3319,~~793~~196	$	63,666

Table of Contents

Cash Flow Hedges

The Company has designated a portion of its forward foreign exchange contracts as cash flow hedges and recorded these contracts at fair value on the condensed consolidated balance sheets. For these instruments, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into income in the same period or periods during which the hedged transaction affects income. As of ~~January~~April 3130, 2025 and July 31, 2024, unrealized losses of $~~529~~742 and $124 have been included in OCI, respectively.

Net Investment Hedges

The Company has designated certain third party foreign currency denominated debt borrowed under its credit agreement as net investment hedges. These debt obligations, denominated in Euros and British Pounds, were designated as net investment hedges to hedge portions of the Company's net investment in its European operations. The Company’s foreign currency denominated debt obligations are valued under a market approach using publicized spot prices, and the net gains or losses attributable to the changes in spot prices are recorded as cumulative translation within AOCI and are included in the foreign currency translation adjustments section of the condensed consolidated statements of comprehensive income. As of ~~January~~April 3130, 2025 and July 31, 2024, the cumulative balances recognized in accumulated other comprehensive income were ~~gains~~losses of $332,850 and ~~losses of~~ $1,237, respectively, on any outstanding foreign currency denominated debt obligations.

The following table summarizes the amount of pre-tax gains and losses related to derivatives designated as hedging instruments:

Three months ended January 31,

Six months ended January 31,

Three months ended April 30,

Nine months ended April 30,

2025

2024

2025

2024

Gains (losses) recognized in OCI:

(Losses) gains recognized in OCI:

Forward exchange contracts (cash flow hedges)

~~935~~(423)

~~1,083~~447

(~~403~~826)

~~789~~1,236

Foreign currency denominated debt (net investment hedges)

1(2,~~460~~883)

~~(969)~~408

(1,~~270~~613)

~~539~~947

(Losses) gains reclassified from OCI into cost of goods sold

Forward exchange contracts (cash flow hedges)

(~~463~~210)

~~254~~173

1(209)

1,~~539~~712

Fair values of derivative instruments in the condensed consolidated balance sheets were as follows:

	January 31, 2025						July 31, 2024
	April 30, 2025						July 31, 2024
	Prepaid expenses and other current assets		Other current liabilities		Long-term obligations		Prepaid expenses and other current assets		Other current liabilities		Long-term obligations
Derivatives designated as hedging instruments:
Foreign exchange contracts (cash flow hedges)	$	~~741~~50	$	~~1,060~~406	$	—	$	137	$	726	$	—
Foreign currency denominated debt (net investment hedges)	—		—		3234,~~790~~633		—		—		34,060
Derivatives not designated as hedging instruments:
Foreign exchange contracts (non-designated hedges)	—		151		—		—		4		—
Total derivative instruments	$	~~741~~50	$	~~1,075~~407	$	3234,~~790~~633	$	137	$	730	$	34,060

NOTE L — Income Taxes

The income tax rate for the three months ended ~~January~~April 3130, 2025 and 2024 was 2220.5% and 21.80%, respectively. The income tax rate for both of the ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, was 21.~~4% and 21.~~1%~~, respectively~~.

Table of Contents

NOTE M — Contingencies

In the normal course of business, the Company is subject to a variety of investigations, claims, suits, and other legal proceedings, including but not limited to, intellectual property, employment, unclaimed property, tort, and breach of contract matters. Any legal proceedings are subject to inherent uncertainties, and these matters and their potential effects may change in the future. The Company records a liability for contingencies when a loss is deemed to be probable and the loss can be reasonably estimated. The Company currently believes that the outcomes of such proceedings will not have a material adverse impact on its business, financial position, results of operations or cash flows.

NOTE N — Acquisitions

On August 1, 2024, the Company acquired all of the outstanding shares of Gravotech. Headquartered in Lyon, France, Gravotech is a leader in the design, manufacture and distribution of innovative solutions for specialized engraving, marking and cutting, offering laser, mechanical engraving, scribing and dot peen capabilities across multiple industries. The acquisition of Gravotech expands the Company’s identification product offerings and research and development capabilities to include specialized direct part marking and engraving expertise. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. Net sales and net loss attributable to Gravotech from the acquisition date through ~~January~~April 3130, 2025 were $5685,~~853~~528 and $810,~~266~~439, respectively. The net loss attributable to Gravotech is due to a non-recurring increase in cost of goods sold related to the fair value adjustment to inventory upon acquisition and amortization expense for intangible assets.

The preliminary purchase price allocation included goodwill of $69,936 of which $48,586 was assigned to the Americas & Asia segment and $21,350 was assigned to the Europe & Australia segment.

The following table summarizes the preliminary fair value of the assets acquired and liabilities assumed at the date of the acquisition:


Cash and cash equivalents	$	7,469
Accounts receivable, net	23,697
Inventories	21,190
Prepaid expenses and other current assets	549
Property, plant and equipment — net	2,472
Goodwill	69,936
Other intangible assets	64,099
Operating lease assets	6,800
Other assets	1,034
Accounts payable	(17,353)
Accrued compensation and benefits	(9,106)
Taxes, other than income taxes	(6,680)
Accrued income taxes	(1,807)
Other current liabilities	(17,688)
Operating lease liabilities	(6,800)
Other liabilities	(6,729)
Net assets acquired	$	131,083
Less: cash acquired	(7,469)

Fair value of total consideration	$	123,614

The final purchase price allocation is subject to post-closing adjustments pursuant to the terms of the securities sale and purchase agreement, as well as the finalization of certain accounts, primarily intangible assets and deferred tax adjustments. The goodwill for this acquisition is not deductible for tax purposes.

Table of Contents

The following table presents the unaudited pro forma operating results of the Company for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, reflecting the acquisition of Gravotech as if it had occurred at the beginning of fiscal year 2024. The unaudited pro forma operating results for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 do not contain any adjustments to the accompanying condensed consolidated financial statements. The unaudited pro forma operating results for the three and ~~six~~nine months ended ~~January~~April 3130, 2024 include Gravotech’s normal operating results and pro forma adjustments to include cumulative expenses, net of tax, for the non-recurring fair value adjustment to inventory, amortization expense for acquired intangible assets and interest expense on acquisition-related debt. The unaudited pro forma operating results are presented for comparative purposes only and do not necessarily reflect future operating results or those that would have occurred had the acquisition been completed at the beginning of fiscal year 2024.

Three months ended January 31,

Six months ended January 31,

Three months ended April 30,

Nine months ended April 30,

2025

2024

2025

2024

Net sales, pro forma

~~356~~382,~~675~~590

~~352~~371,~~412~~732

~~733~~1,~~740~~116,330

~~713~~1,~~521~~085,253

Net income, pro forma

4052,~~334~~263

4348,~~384~~339

87139,~~117~~380

86135,~~918~~257

On October 1, 2024, the Company acquired all of the outstanding shares of AB&R for $1514,~~625~~827, net of cash acquired. Based in Phoenix, Arizona, AB&R provides integrated solutions for asset tracking, inventory management, and workflow optimization using advanced identification and tracking technologies, including barcoding, radio frequency identification (“RFID”) and Internet of Things (“IoT”)-based systems. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. The Company recorded its preliminary purchase price allocation during the first quarter of fiscal year 2025, based on its estimates of the fair value of the acquired assets and assumed liabilities at that time. The preliminary purchase price allocation included goodwill of $10,~~877~~079, intangible assets of $4,600, and net tangible assets of $148. The goodwill for this acquisition is assigned to the Americas & Asia segment and is deductible for tax purposes. The final purchase price allocation is subject to post-closing adjustments and the finalization of certain intangible asset valuations and deferred tax adjustments, as well as potential contingent consideration subject to AB&R’s achievement of certain post-acquisition financial targets pursuant to the terms of the membership interest purchase agreement. Acquisition-related expenses of $305 were recognized in selling, general and administrative (“SG&A”) expenses during the ~~six~~nine months ended ~~January~~April 3130, 2025. The accompanying condensed consolidated financial statements include the results of AB&R from the date of acquisition through ~~January 31~~April 30, 2025. Pro forma and other financial information are not presented for the AB&R acquisition because its impact on the Company's results of operation and financial position is immaterial.

On April 1, 2025, the Company acquired certain assets and liabilities representing the Microfluidic Solutions business unit of Funai Electric Co., Ltd., for $11,648. Headquartered in Lexington, Kentucky, with a manufacturing facility in Cebu, Philippines, Microfluidic Solutions specializes in the research, development and manufacturing of advanced inkjet microfluidic technologies. The acquisition was funded through cash on hand and borrowings under the Company’s existing credit agreement. The Company recorded its preliminary purchase price allocation during the third quarter of fiscal year 2025, based on its estimates of the fair value of the acquired assets and assumed liabilities at that time. The preliminary purchase price allocation included property, plant and equipment of $12,090, inventories of $3,028, other intangible assets of $1,544, accounts payable of $1,111, and other liabilities of $3,903. The final purchase price allocation is subject to post-closing adjustments and the finalization of certain tangible asset valuations, intangible asset valuations and deferred tax adjustments. The accompanying condensed consolidated financial statements include the results of Microfluidic Solutions from the date of acquisition through April 30, 2025. Pro forma and other financial information are not presented for the Microfluidic Solutions acquisition because its impact on the Company's results of operation and financial position is immaterial.

NOTE O — Subsequent Events

On May 15, 2025, the Board of Directors declared a quarterly cash dividend to shareholders of the Company’s Class A and Class B Common Stock of $0.24 per share payable on July 31, 2025, to shareholders of record at the close of business on July 10, 2025.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Brady Corporation is a global manufacturer and supplier of identification solutions and workplace safety products that identify and protect premises, products and people. The Company is organized and managed on a geographic basis with two reportable segments: Americas & Asia and Europe & Australia. This regional operating structure allows the Company to further integrate its businesses, support continued growth through the application of the best go-to-market strategies in key geographies, facilitate new product development within recent acquisitions and further simplify and scale the global business.

Within each of the reportable segments, the Company markets, sells and distributes a broad range of identification and safety products and solutions across the following primary product categories:

•Safety and facility identification and protection, which includes safety signs, traffic signs and control products, floor-marking tape, pipe markers, labeling systems, spill control products, lockout/tagout devices, personal protection equipment, first aid products, and software and services for safety compliance auditing, procedures writing and training.

•Product identification, which includes materials, printing systems, radio frequency identification (“RFID”) and barcode scanners for product identification, engraving equipment, brand protection labeling, work in process labeling, finished product identification, asset tracking labels, asset tags and industrial track and trace applications.

•Wire identification, which includes handheld printers, wire markers, sleeves, and tags.

•Healthcare identification, which includes wristbands, labels, printing systems, and other products used in hospital, laboratory, and other healthcare settings for tracking and improving the safety of patients.

•People identification, which includes name tags, badges, lanyards, rigid card printing systems, and access control software.

The ability to provide customers with a broad range of proprietary, customized and diverse products for use in various applications across multiple industries and geographies, along with a commitment to quality and service, have made Brady a leader in many of its markets. Brady's long-term sales growth and profitability will depend not only on the overall economic environment and our ability to successfully navigate changes in the macro environment, but also on our ability to develop and market innovative products, deliver a high level of customer service, advance our digital capabilities, and continuously improve the efficiency of our global operations. Our strategy for growth includes an increased focus on certain industries and products, streamlining our product offerings, expanding into higher growth end-markets, intensifying efforts to leverage our diverse product portfolio and synergies across our business, improving the overall customer experience, developing technologically advanced, innovative, and proprietary products, and improving our digital capabilities.

The following are key initiatives supporting our strategy in fiscal 2025:

•Investing in organic growth by enhancing our research and development process and utilizing customer feedback and observations to develop innovative new products that solve customer needs and improve environmental sustainability.

•Providing the highest level of customer service by aligning with customers' preferred communications channels and leveraging technology to enhance the customer experience.

•Expanding and enhancing our sales capabilities through an improved digital presence and the use of data-driven marketing automation tools.

•Maintaining profitability through pricing mechanisms to mitigate the impacts of ongoing supply chain disruptions and inflationary pressures while ensuring prices are market competitive.

•Integrating recent acquisitions to further enhance our strategic position and accelerate long-term sales growth.

•Driving operational excellence and executing sustainable efficiency gains within our selling, general and administrative structures and within our global operations including insourcing of critical products and manufacturing activities while reducing our environmental footprint.

•Enhancing our high-performance culture, which rewards execution and respects diversity, to elevate employee engagement and improve recruitment and retention practices in order to drive differential performance and execute our strategy.

Macroeconomic Conditions and Trends

The Company's operations and financial performance are subject to the risks and uncertainties inherent in the global economic environment, including inflationary pressures, supply chain disruptions, and other macroeconomic challenges. These pressures may impact the Company's business, financial condition and results of operations as the global economic outlook remains uncertain. ~~The Company has taken and will continue to take actions to mitigate inflationary pressures through targeted pricing actions and a commitment to driving long-term efficiency improvements.~~

Table of Contents

WeIn ~~believe~~recent ~~our~~months, ~~financial~~the ~~strength~~U.S. ~~positions~~government usintroduced ~~well~~incremental toimport ~~continue~~tariffs ~~investing~~on ingoods ~~acquisitions~~imported ~~and~~into ~~organic~~the ~~growth~~U.S. ~~opportunities~~from numerous countries, ~~such~~triggering asreciprocal ~~expanded~~tariffs ~~sales~~and ~~channels~~other actions from many trading partners on goods exported from the U.S. Trade policies of the U.S. and other countries, ~~marketing~~including ~~programs~~China, ~~and~~are ~~research~~complex and ~~development~~rapidly ~~(“R&D”)~~evolving. WeOur ~~remain~~strategy ~~focused~~of onmanufacturing ~~driving~~products ~~sustainable~~near ~~efficiency~~the ~~gains~~point ~~and~~of ~~automation~~sale ~~across~~reduces our ~~operations~~overall ~~and~~exposure ~~selling~~to tariffs, ~~general~~though ~~and~~certain ~~administrative~~sourced ~~(“SG&A”)~~inputs ~~functions,~~and ~~while~~manufactured ~~also~~items ~~returning~~remain ~~capital~~subject to ~~our~~incremental ~~shareholders~~tariffs. ~~through~~Our ~~dividends~~business has incurred, and ~~share~~expects ~~repurchases.~~to Atcontinue ~~January 31,~~to ~~2025~~incur, weadditional ~~had~~costs ~~cash~~as ofit ~~$138.5~~relates ~~million,~~to asthese ~~well~~incremental astariffs afor ~~credit~~the ~~agreement~~remainder ~~with~~of ~~$210.1~~fiscal ~~million~~2025 ~~available~~and ~~for~~the foreseeable future. ~~borrowing,~~The ~~which~~Company ~~can~~has betaken ~~increased~~and upwill continue to ~~$1,095.1~~take ~~million~~action atto mitigate inflationary pressures caused by the ~~Company's~~incremental ~~option~~tariffs ~~and~~through ~~subject~~a tocombination ~~certain~~of ~~conditions~~targeted price increases and surcharges, ~~for~~strategic ~~total~~sourcing ~~available~~adjustments, ~~liquidity~~product ofportfolio $1optimization,~~233.6~~ ~~million~~as well as our ongoing efforts to drive sustainable efficiency gains in our operations and administrative structures.

Notwithstanding the fluid situation relating to tariffs, we believe our financial strength positions us well to continue investing in acquisitions and organic growth opportunities, such as expanded sales channels, marketing programs, and research and development (“R&D”). We remain focused on driving sustainable efficiency gains and automation across our operations and selling, general and administrative (“SG&A”) functions, while also returning capital to our shareholders through dividends and share repurchases. At April 30, 2025, we had cash of $152.2 million, as well as a credit agreement with $195.2 million available for future borrowing, which can be increased to $1,085.2 million at the Company's option and subject to certain conditions, for total available liquidity of $1,237.4 million.

We believe that our financial resources and liquidity levels, including the undrawn portion of our credit agreement and our ability to increase that credit line as necessary, are sufficient to support the execution of our growth strategy and to manage the impact of economic or geopolitical events that could potentially reduce sales, net income, or cash provided by operating activities. Refer to Risk Factors, included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended July 31, 2024, for further discussion of the possible impact of global economic or geopolitical events on our business.

Results of Operations

The comparability of the operating results for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 compared to the same periods in the prior year have been impacted by the acquisitions of Gravotech on August 1, 2024, ~~and~~ AB&R on October 1, 2024 and Microfluidic Solutions on April 1, 2025. The operating results of Gravotech, ~~and~~ AB&R and Microfluidic Solutions have been included since their acquisition dates. Gravotech has been included in both reportable segments, and AB&R ~~has~~and Microfluidic Solutions have been included in the Americas & Asia reportable segment. The comparability of the year-to-date operating results of the Americas & Asia segment has also been impacted by the divestiture of a non-core business in October 2023.

A comparison of results of operating income for the three and ~~six~~nine months ended ~~January~~April 3130, 2025 and 2024, is as follows:

	Three months ended January 31,								Six months ended January 31,
	Three months ended April 30,								Nine months ended April 30,
(Dollars in thousands)	2025		% Sales		2024		% Sales		2025		% Sales		2024		% Sales
Net sales	$	~~356~~382,~~675~~590			$	~~322~~343,~~624~~384			$	~~733~~1,~~740~~116,330			$	~~654~~997,~~607~~991
Gross margin	~~175~~195,~~843~~059		4951.30	%	~~162~~177,~~083~~027		5051.26	%	~~365~~560,~~532~~591		4950.82	%	~~333~~510,~~802~~829		51.02	%
Operating expenses:
Research and development	1819,~~723~~191		5.20	%	1617,~~832~~681		5.21	%	3756,~~644~~835		5.1	%	3250,~~534~~215		5.0	%
Selling, general and administrative	~~105~~108,~~886~~678		2928.74	%	9195,~~325~~803		2827.39	%	~~217~~326,~~732~~410		29.72	%	~~187~~283,~~612~~415		28.74	%
Total operating expenses	~~124~~127,~~609~~869		3433.94	%	~~108~~113,~~157~~484		33.50	%	~~255~~383,~~376~~245		34.83	%	~~220~~333,~~146~~630		33.64	%
Operating income	$	5167,~~234~~190	1417.46	%	$	5363,~~926~~543	1618.75	%	$	~~110~~177,~~156~~346	15.09	%	$	~~113~~177,~~656~~199	17.48	%

References in this Form 10-Q to “organic sales” refer to sales calculated in accordance with GAAP, excluding the impact of foreign currency translation, sales recorded from acquired companies prior to the first anniversary date of their acquisition, and sales recorded from divested companies up to the first anniversary of their divestiture. The Company's organic sales disclosures exclude the effects of foreign currency translation as foreign currency translation is subject to volatility that can obscure underlying business trends. Management believes that the non-GAAP financial measure of organic sales is meaningful to investors as it provides them with useful information to aid in identifying underlying sales trends in our businesses and facilitating comparisons of our sales performance with prior periods.

Net sales for the three months ended ~~January~~April 3130, 2025 increased 1011.64% to $~~356~~382.76 million compared to $~~322~~343.64 million in the same period in the prior year. The increase consisted of organic sales growth of 21.6% and sales growth from acquisitions of 10.25%, which was partially offset by a decrease from foreign currency translation of 20.27%. Organic sales growth of 45.34% in the Americas & Asia segment was partially offset by an organic sales decline of 05.84% in the Europe & Australia segment during the three months ended ~~January~~April 3130, 2025 compared to the same period in the prior year.

Net sales for the six months ended January 31, 2025 increased 12.1% to $733.7 million compared to $654.6 million in the same period in the prior year. The increase consisted of organic sales growth of 3.1% and sales growth from acquisitions of 10.0%, partially offset by a decrease from foreign currency translation of 0.5% and a decrease of 0.5% due to a divestiture. Organic sales grew 4.7% in the Americas & Asia segment and were flat in the Europe & Australia segment during the six months ended January 31, 2025 compared to the same period in the prior year.

Table of Contents

~~Gross~~Net ~~margin~~sales ~~increased~~for ~~8.5% to $175.8 million in~~ the ~~three~~nine months ended ~~January~~April 3130, 2025 ~~compared to $162.1 million in the same period in the prior year. As a percentage of net sales, gross margin decreased to 49.3% from 50.2% in the three-month period. Gross margin~~ increased 911.59% to $~~365~~1,116.53 million ~~in the six months ended January 31, 2025~~ compared to $~~333~~998.80 million in the same period in the prior year. AsThe aincrease ~~percentage~~consisted of ~~net~~organic sales, ~~gross~~growth ~~margin~~of ~~decreased to 49~~2.86% ~~from~~and ~~51.0% in the six-month period. The decrease in gross margin as a percentage of net~~ sales ~~during~~growth ~~the~~from ~~three~~acquisitions ~~months ended January 31, 2025 was primarily due to facility closure and other reorganization costs~~ of $210.~~3 million~~2%, ~~which were~~ partially offset by ~~organic~~a ~~sales~~decrease ~~growth~~from inforeign ~~higher~~currency ~~gross~~translation ~~margin~~of ~~product lines~~0.5% ~~The facility closure~~ and ~~other~~a ~~reorganization~~decrease ~~costs~~of ~~primarily~~0.4% ~~relate~~due to ~~headcount~~a ~~reductions~~divestiture. ~~associated~~Organic ~~with~~sales ~~the~~grew ~~closure~~5.0% ~~of a manufacturing facility~~ in ~~China and~~ the ~~closure~~Americas of& aAsia ~~manufacturing~~segment, ~~facility~~while inorganic ~~the~~sales Udeclined 1.S.9% ~~The decrease~~ in ~~gross~~the ~~margin~~Europe as& aAustralia ~~percentage~~segment ~~of net sales~~ during the ~~six~~nine months ended ~~January~~April 3130, 2025 ~~was~~compared ~~primarily due~~ to athe ~~non-recurring~~same ~~increase~~period in ~~cost of goods sold of $4.1 million related to~~ the ~~fair~~prior ~~value adjustment to inventory from acquisitions as well as the facility closure and other reorganization costs of $2~~year.~~3 million, which were partially offset by organic sales growth in higher gross margin product lines.~~

~~R&D~~Gross ~~expenses~~margin increased 1110.2% to $18195.71 million in the three months ended ~~January~~April 3130, 2025 compared to $16177.80 million in the same period in the prior year. As a percentage of net sales, ~~R&D~~gross ~~expenses~~margin ~~were~~decreased ~~unchanged~~to at51.0% 5from 51.26% in the three-month period ~~compared to the same period in the prior year~~. ~~R&D~~Gross ~~expenses~~margin increased 159.7% to $37560.6 million in the ~~six~~nine months ended ~~January~~April 3130, 2025 compared to $32510.58 million in the same period in the prior year. As a percentage of net sales, ~~R&D~~gross ~~expenses~~margin ~~increased~~decreased to 550.12% from 551.02% in the ~~six~~nine-month period. The ~~increase~~decrease in ~~R&D~~gross ~~spending~~margin as a percentage of net sales during the three-month period was primarily due to the ~~acquisition~~impact of ~~Gravotech,~~incremental ~~and~~tariffs, primarily on goods imported to athe ~~lesser~~U.S. ~~extent~~from China, anand ~~increase~~$1.1 inmillion ~~R&D~~of ~~headcount~~facility ~~within~~closure ~~the~~and ~~Company's~~other reorganization costs, which were partially offset by organic ~~business~~sales growth in higher gross margin product lines. The ~~Company~~decrease ~~remains~~in ~~committed~~gross tomargin ~~investing~~as ina ~~new~~percentage ~~product~~of ~~development~~net sales during the nine months ended April 30, 2025 was primarily due to ~~drive~~a ~~long~~non-~~term~~recurring ~~organic~~increase ~~sales~~in ~~growth~~cost of goods sold of $4.1 ~~Investments~~million inrelated ~~new~~to ~~printing~~the ~~systems~~fair value adjustment to inventory from acquisitions, ~~materials~~facility closure and ~~new~~other ~~product~~reorganization ~~development~~costs ~~within~~of ~~recent~~$3.0 ~~acquisitions~~million, ~~are~~as ~~the~~well ~~primary~~as ~~focus~~the impact of ~~R&D~~incremental ~~expenditures~~tariffs, which were partially offset by organic sales growth in ~~fiscal~~higher ~~2025~~gross margin product lines.

SGR&AD expenses include selling and administrative costs directly attributed to the Americas & Asia and Europe & Australia segments, as well as certain other corporate administrative expenses including finance, information technology, human resources and other administrative expenses. SG&A expenses increased 158.95% to $~~105~~19.92 million in the three months ended ~~January~~April 3130, 2025 compared to $9117.37 million in the same period in the prior year. As a percentage of net sales, SGR&AD expenses ~~increased~~decreased to 295.70% ~~from~~in 28the three-month period compared to 5.31% in the ~~three-month~~same period in the prior year. SGR&AD expenses increased 1613.12% to $~~217~~56.78 million ~~for~~in the ~~six~~nine months ended ~~January~~April 3130, 2025 compared to $~~187~~50.62 million in the same period in the prior year. As a percentage of net sales, SGR&AD expenses increased to 295.71% from 285.70% in the ~~six~~nine-month period. The increase in SGR&AD ~~expenses~~spending ~~during the three and six months ended January 31, 2025~~ was primarily due to ~~increased~~the ~~headcount~~acquisition ~~and~~of ~~other~~Gravotech, ~~selling-related costs from acquisitions~~and, ~~including~~to ~~incremental~~a ~~amortization~~lesser ~~expense~~extent, ~~from~~an ~~the~~increase ~~acquired~~in ~~intangible assets. SG~~R&AD ~~expenses~~headcount ~~during~~within the ~~three~~Company's ~~months~~organic ~~ended~~business. ~~January~~The ~~31,~~Company ~~2025~~remains ~~also~~committed ~~include~~to ~~facility~~investing ~~closure~~in ~~and~~new ~~other~~product ~~reorganization~~development ~~costs~~to ofdrive ~~$3.4~~long-term ~~million.~~organic ~~SG&A~~sales ~~expenses~~growth. ~~during~~Investments ~~the~~in ~~six~~new ~~months~~printing ~~ended January 31~~systems, ~~2025~~materials ~~also include facility closure~~ and ~~other~~new ~~reorganization~~product ~~costs~~development ofwithin ~~$3.4~~recent ~~million~~acquisitions ~~and~~are ~~non-recurring~~the ~~acquisition-related~~primary ~~costs~~focus ~~and~~of ~~other~~R&D ~~expenses~~expenditures ofin ~~$1.0~~fiscal ~~million~~2025.

~~Operating~~SG&A ~~income~~expenses ~~decreased~~include ~~5.0%~~selling and administrative costs directly attributed to ~~$51.2~~the ~~million~~Americas & Asia and ~~decreased~~Europe 3& Australia segments, as well as certain other corporate administrative expenses including finance, information technology, human resources and other administrative expenses.1 SG&A expenses increased 13.4% to $~~110~~108.27 million in the three ~~and six~~ months ended ~~January~~April 3130, 2025, ~~respectively,~~ compared to $5395.8 million in the same period in the prior year. As a percentage of sales, SG&A expenses increased to 28.4% from 27.9% in the three-month period. SG&A expenses increased 15.2% to $326.4 million ~~and~~for the nine months ended April 30, 2025 compared to $~~113~~283.74 million in the same ~~periods~~period in the prior year. ~~The~~As ~~decrease~~a percentage of net sales, SG&A expenses increased to 29.2% from 28.4% in ~~operating~~the ~~income~~nine-month period. The increase in ~~both~~SG&A expenses during the three and ~~six-month~~nine ~~periods~~months ended April 30, 2025 was primarily due to ~~non-recurring~~increased ~~acquisition~~headcount and other selling-related costs ~~and~~from acquisitions, including incremental amortization expense ~~related~~from tothe acquired ~~businesses~~intangible assets. Amortization expense increased $2.4 million and $7.1 million during the three and nine months ended April 30, as2025 ~~well~~compared asto the same periods in the prior year. SG&A expenses during the three and nine months ended April 30, 2025 also include facility closure and other reorganization costs of $2.8 million and $6.6 million, respectively. SG&A expenses during the nine months ended April 30, 2025 also include non-recurring acquisition-related costs and other expenses of $1.0 million.

~~OPERATING~~Operating ~~INCOME~~income TOincreased ~~NET~~5.7% ~~INCOME~~to $67.2 million and increased 0.1% to $177.3 million in the three and nine months ended April 30, 2025, respectively, compared to $63.5 million and $177.2 million in the same periods in the prior year. The increase in operating income in both the three and nine-month periods was primarily due to organic sales growth in higher gross margin product lines, which was partially offset by non-recurring acquisition-related costs and incremental amortization expense related to acquired businesses, as well as facility closure and other reorganization costs.

	Three months ended January 31,								Six months ended January 31,
(Dollars in thousands)	2025		% Sales		2024		% Sales		2025		% Sales		2024		% Sales
Operating income	$	51,234	14.4	%	$	53,926	16.7	%	$	110,156	15.0	%	$	113,656	17.4	%
Other income (expense):
Investment and other income	2,125		0.6	%	2,684		0.8	%	3,359		0.5	%	3,122		0.5	%
Interest expense	(1,312)		(0.4)	%	(790)		(0.2)	%	(2,668)		(0.4)	%	(1,556)		(0.2)	%
Income before income taxes	52,047		14.6	%	55,820		17.3	%	110,847		15.1	%	115,222		17.6	%
Income tax expense	11,713		3.3	%	12,192		3.8	%	23,730		3.2	%	24,353		3.7	%
Net income	$	40,334	11.3	%	$	43,628	13.5	%	$	87,117	11.9	%	$	90,869	13.9	%

Investment and other income was $2.1 million in the three months ended January 31, 2025 compared to $2.7 million in the same period in the prior year. Investment and other income was $3.4 million in the six months ended January 31, 2025 compared to $3.1 million in the same period in the prior year. The change in investment and other income during both the three and six-month periods was primarily due to the change in market value of securities held in deferred compensation plans.

Table of Contents

~~Interest~~OPERATING ~~expense~~INCOME ~~increased~~TO toNET $1.3 million and $2.7 million for the three and six months ended January 31, 2025, respectively, compared to $0.8 million and $1.6 million in the same periods in the prior year. The increase in interest expense was primarily due to an increase in outstanding borrowings on the Company's credit agreement to fund acquisitions, which was partially offset by a decrease in the weighted average interest rate compared to the same periods in the prior year.INCOME

The Company's income tax rate was 22.5% and 21.8% for the three months ended January 31, 2025 and 2024, respectively, and the income tax rate was 21.4% and 21.1% for the six months ended January 31, 2025 and 2024, respectively. The Company expects its ongoing annual income tax rate to be approximately 21% based on its current global business mix and based on tax laws and statutory rates currently in effect.


	Three months ended April 30,								Nine months ended April 30,
(Dollars in thousands)	2025		% Sales		2024		% Sales		2025		% Sales		2024		% Sales
Operating income	$	67,190	17.6	%	$	63,543	18.5	%	$	177,346	15.9	%	$	177,199	17.8	%
Other (expense) income:
Investment and other (expense) income	(509)		(0.1)	%	1,596		0.5	%	2,850		0.3	%	4,718		0.5	%
Interest expense	(936)		(0.2)	%	(728)		(0.2)	%	(3,604)		(0.3)	%	(2,284)		(0.2)	%
Income before income taxes	65,745		17.2	%	64,411		18.8	%	176,592		15.8	%	179,633		18.0	%
Income tax expense	13,482		3.5	%	13,521		3.9	%	37,212		3.3	%	37,874		3.8	%
Net income	$	52,263	13.7	%	$	50,890	14.8	%	$	139,380	12.5	%	$	141,759	14.2	%

Investment and other (expense) income was a net expense of $0.5 million in the three months ended April 30, 2025 compared to net investment income of $1.6 million in the same period in the prior year. Investment and other (expense) income decreased to $2.9 million of net investment income in the nine months ended April 30, 2025 compared to $4.7 million in the same period in the prior year. The change in investment and other (expense) income during both the three and nine-month periods was primarily due to the change in market value of securities held in deferred compensation plans.

Interest expense increased to $0.9 million and $3.6 million for the three and nine months ended April 30, 2025, respectively, compared to $0.7 million and $2.3 million in the same periods in the prior year. The increase in interest expense was primarily due to an increase in outstanding borrowings on the Company's credit agreement to fund acquisitions, which was partially offset by a decrease in the weighted average interest rate compared to the same periods in the prior year.

The Company's income tax rate was 20.5% and 21.0% for the three months ended April 30, 2025 and 2024, respectively, and the income tax rate was 21.1% for both of the nine-month periods ended April 30, 2025 and 2024. The Company expects its ongoing annual income tax rate to be approximately 21% based on its current global business mix and based on tax laws and statutory rates currently in effect.

Business Segment Operating Results

The Company evaluates short-term segment performance based on segment profit and customer sales. Interest expense, investment and other income, income tax expense, and certain corporate administrative expenses are excluded when evaluating segment performance.

The following is a summary of segment information for the three and six months ended January 31, 2025 and 2024:

	Three months ended January 31,						Six months ended January 31,
	2025			2024			2025			2024
SALES GROWTH INFORMATION
Americas & Asia
Organic	4.3		%	1.2		%	4.7		%	2.3		%
Acquisitions	7.6		%	—		%	7.5		%	—		%
Currency	(1.4)		%	0.1		%	(0.8)		%	—		%
Divestiture	—		%	(5.1)		%	(0.8)		%	(3.5)		%
Total	10.5		%	(3.8)		%	10.6		%	(1.2)		%
Europe & Australia
Organic	(0.8)		%	2.5		%	—		%	2.0		%
Acquisitions	15.1		%	—		%	15.1		%	—		%
Currency	(3.6)		%	2.0		%	(0.1)		%	3.3		%
Total	10.7		%	4.5		%	15.0		%	5.3		%
Total Company
Organic	2.6		%	1.6		%	3.1		%	2.2		%
Acquisitions	10.2		%	—		%	10.0		%	—		%
Currency	(2.2)		%	0.8		%	(0.5)		%	1.1		%
Divestiture	—		%	(3.5)		%	(0.5)		%	(2.4)		%
Total	10.6		%	(1.1)		%	12.1		%	0.9		%
SEGMENT PROFIT
Americas & Asia	$	45,986		$	43,895		$	100,886		$	93,792
Europe & Australia	11,378			15,054			24,492			31,798
Total	$	57,364		$	58,949		$	125,378		$	125,590
SEGMENT PROFIT AS A PERCENT OF NET SALES
Americas & Asia	19.7		%	20.7		%	21.0		%	21.6		%
Europe & Australia	9.3		%	13.6		%	9.6		%	14.4		%
Total	16.1		%	18.3		%	17.1		%	19.2		%

Americas & Asia

Americas & Asia net sales increased 10.5% to $233.8 million in the three months ended January 31, 2025 compared to $211.6 million in the same period in the prior year, which consisted of organic sales growth of 4.3% and sales growth from acquisitions of 7.6%, which were partially offset by a decrease from foreign currency translation of 1.4%. Americas & Asia net sales increased 10.6% to $479.3 million in the six months ended January 31, 2025 compared to $433.3 million in the same period in the prior year, which consisted of organic sales growth of 4.7% and sales growth from acquisitions of 7.5%, which were partially offset by a decrease from foreign currency translation of 0.8% and a decrease due to a divestiture of 0.8%.

Table of Contents

~~Organic~~The ~~sales~~following inis ~~the~~a ~~Americas~~summary ~~increased~~of insegment ~~the~~information ~~low-single~~for ~~digits in~~ the three ~~months ended January 31, 2025~~ and innine ~~the mid-single digits in the six~~ months ended ~~January~~April 3130, 2025 ~~compared to the same periods in the prior year. Organic sales growth in both the three~~ and six-month periods was driven by growth in the wire identification, safety and facility identification, and product identification product lines, which was partially offset by an organic sales decline in the healthcare identification product line.2024:

Organic sales in Asia increased approximately 11% in the three months ended January 31, 2025 and increased in the high-single digits in the six months ended January 31, 2025 compared to the same periods in the prior year. The organic sales increase in both the three and six-month periods was primarily driven by organic sales growth in Japan and India, which was partially offset by an organic sales decline in China. Organic sales grew in all major products lines with the strongest growth in the product identification and safety and facility identification product lines.


	Three months ended April 30,						Nine months ended April 30,
	2025			2024			2025			2024
SALES GROWTH INFORMATION
Americas & Asia
Organic	5.4		%	4.5		%	5.0		%	3.0		%
Acquisitions	8.6		%	—		%	7.9		%	—		%
Currency	(1.1)		%	(0.1)		%	(1.0)		%	—		%
Divestiture	—		%	(3.5)		%	(0.5)		%	(3.5)		%
Total	12.9		%	0.9		%	11.4		%	(0.5)		%
Europe & Australia
Organic	(5.4)		%	4.4		%	(1.9)		%	2.8		%
Acquisitions	14.2		%	—		%	14.2		%	—		%
Currency	(0.1)		%	(0.6)		%	(0.1)		%	1.9		%

Total	8.7		%	3.8		%	12.8		%	4.7		%
Total Company
Organic	1.6		%	4.5		%	2.6		%	3.0		%
Acquisitions	10.5		%	—		%	10.2		%	—		%
Currency	(0.7)		%	(0.3)		%	(0.5)		%	0.6		%
Divestiture	—		%	(2.3)		%	(0.4)		%	(2.4)		%
Total	11.4		%	1.9		%	11.9		%	1.2		%
SEGMENT PROFIT
Americas & Asia	$	57,164		$	49,697		$	158,148		$	143,489
Europe & Australia	17,478			19,537			41,872			51,335
Total	$	74,642		$	69,234		$	200,020		$	194,824
SEGMENT PROFIT AS A PERCENT OF NET SALES
Americas & Asia	22.5		%	22.1		%	21.6		%	21.8		%
Europe & Australia	13.6		%	16.5		%	10.9		%	15.1		%
Total	19.5		%	20.2		%	17.9		%	19.5		%

Americas & Asia segment profit increased 4.8% to $46.0 million in the three months ended January 31, 2025 compared to $43.9 million in the same period in the prior year. Segment profit increased 7.6% to $100.9 million in the six months ended January 31, 2025 compared to $93.8 million in the same period in the prior year. As a percentage of net sales, segment profit decreased to 19.7% from 20.7% in the three-month period and segment profit decreased to 21.0% from 21.6% in the six-month period ended January 31, 2025 compared to the same periods in the prior year. The decrease in segment profit as a percentage of sales was primarily due to costs associated with the closure of two facilities during the three-month period, and incremental amortization from acquired businesses and purchase accounting adjustments during the six-month period, which was partially offset by increased profit from organic sales growth.

~~Europe~~Americas & ~~Australia~~Asia net sales increased 12.9% to $253.7 million in the three months ended April 30, 2025 compared to $224.8 million in the same period in the prior year, which consisted of organic sales growth of 5.4% and sales growth from acquisitions of 8.6%, which were partially offset by a decrease from foreign currency translation of 1.1%. Americas & Asia net sales increased 11.4% to $732.9 million in the nine months ended April 30, 2025 compared to $658.0 million in the same period in the prior year, which consisted of organic sales growth of 5.0% and sales growth from acquisitions of 7.9%, which were partially offset by a decrease from foreign currency translation of 1.0% and a decrease due to a divestiture of 0.5%.

~~Europe~~Organic &sales ~~Australia~~in ~~net~~the ~~sales~~Americas increased ~~10.7%~~in tothe ~~$122.8~~low-single ~~million~~digits in both the three and nine months ended ~~January~~April 3130, 2025 compared to ~~$111.0 million in~~ the same ~~period~~periods in the prior year,. ~~which~~Organic ~~consisted of~~ sales growth ~~from~~in ~~acquisitions~~both ofthe ~~15.1%~~three ~~that~~and ~~was~~nine-month ~~partially~~periods ~~offset~~was driven by angrowth ~~organic~~in ~~sales~~the ~~decline~~wire ofidentification, ~~0.8%~~safety and afacility ~~decrease~~identification ~~from~~and ~~foreign~~product ~~currency~~identification ~~translation~~product ~~of 3~~lines.~~6%.~~ ~~Europe~~Organic &sales ~~Australia~~growth ~~net~~was ~~sales~~partially ~~increased~~offset ~~15.0%~~by toan ~~$254.5~~organic ~~million~~sales decline in the ~~six~~people ~~months~~identification ~~ended~~product ~~January~~line ~~31, 2025 compared to $221.3 million~~ in the ~~same~~three ~~period~~months inended ~~the~~April ~~prior~~30, ~~year~~2025, ~~which~~and ~~consisted~~an oforganic sales ~~growth~~decline ~~from~~in ~~acquisitions~~the ofhealthcare ~~15.1%,~~identification ~~which~~product ~~was~~line ~~partially~~in ~~offset~~the bynine amonths ~~decrease~~ended ~~from~~April ~~foreign~~30, ~~currency translation of 0~~2025.~~1% while organic sales were flat.~~

Organic sales in ~~Europe~~Asia ~~were~~increased ~~essentially~~approximately ~~flat~~23% in ~~both~~ the three ~~and six~~ months ended ~~January~~April 3130, 2025., ~~Organic~~and ~~sales~~increased ~~growth~~approximately 13% in the ~~product~~nine ~~identification~~months ~~and~~ended ~~wire~~April ~~identification~~30, ~~product~~2025 ~~lines~~compared ~~was~~to ~~offset~~the bysame anperiods ~~organic sales decline~~ in the ~~safety~~prior ~~and~~year. ~~facility~~The ~~identification~~organic ~~product~~sales ~~line~~increase ~~during~~in the three-month period was realized throughout Asia, which included a return to organic sales growth in China. Organic sales growth ~~during~~in the ~~six~~nine-month period ~~was~~resulted ~~primarily~~from ~~driven~~growth throughout Asia, partially offset by ~~growth~~flat organic sales in China. Organic sales in both the ~~safety~~three and ~~facility~~nine-month ~~identification~~periods ~~and~~were ~~wire~~driven ~~identification~~by ~~product~~growth ~~lines,~~in ~~which~~all ~~was~~major ~~offset~~product bylines, anwith ~~organic~~particularly ~~sales~~strong ~~decline~~growth in the product identification and safety and facility identification product ~~line~~lines.

~~Organic~~Americas ~~sales~~& inAsia ~~Australia~~segment ~~declined~~profit increased 15.0% to $57.2 million in the ~~low-single~~three ~~digits~~months ended April 30, 2025 compared to $49.7 million in ~~both~~the same period in the ~~three~~prior ~~and~~year. ~~six~~Segment profit increased 10.2% to $158.1 million in the nine months ended ~~January~~April 3130, 2025 compared to $143.5 million in the same ~~periods~~period in the prior year. ~~The~~As ~~organic~~a percentage of net sales, ~~decline~~segment ~~was~~profit ~~primarily~~increased ~~driven~~to by22.5% afrom ~~decrease~~22.1% in ~~volume~~the three-month period and segment profit decreased to 21.6% from 21.8% in the ~~safety~~nine-month ~~and~~period ~~facility~~ended ~~and~~April 30, ~~wire~~2025 ~~identification~~compared ~~product~~to ~~lines~~the same periods in the prior year. The decrease in segment profit as a percentage of

Europe & Australia segment profit decreased 24.4% to $11.4 million in the three months ended January 31, 2025 compared to $15.1 million in the same period in the prior year. Segment profit decreased 23.0% to $24.5 million in the six months ended January 31, 2025 compared to $31.8 million in the same period in the prior year. As a percentage of net sales, segment profit decreased to 9.3% from 13.6% for the three-month period and segment profit decreased to 9.6% from 14.4% for the six-month period ended January 31, 2025, compared to the same periods in the prior year. The decrease in segment profit was primarily due to incremental amortization from acquired businesses, purchase accounting adjustments and reorganization costs in order to streamline our operating structure.

Liquidity and Capital Resources

The Company's cash balances are generated and held in numerous locations throughout the world. At January 31, 2025, 94% of the Company's cash and cash equivalents were held outside the United States. The Company's organic and inorganic growth has historically been funded by a combination of cash provided by operating activities and debt financing. The Company believes that its cash flow from operating activities and its borrowing capacity are sufficient to fund its anticipated requirements for working capital, capital expenditures, research and development, common stock repurchases, and dividend payments for the next 12 months. Although the Company believes these sources of cash are currently sufficient to fund domestic operations, annual cash needs could require repatriation of cash to the U.S. from foreign jurisdictions, which may result in additional tax payments.

Table of Contents

sales was primarily due to costs associated with the closure of two facilities, incremental amortization from acquired businesses and purchase accounting adjustments during the nine-month period, which was partially offset by increased profit from organic sales growth.

Europe & Australia

Europe & Australia net sales increased 8.7% to $128.9 million in the three months ended April 30, 2025 compared to $118.6 million in the same period in the prior year, which consisted of sales growth from acquisitions of 14.2% that was partially offset by an organic sales decline of 5.4% and a decrease from foreign currency translation of 0.1%. Europe & Australia net sales increased 12.8% to $383.4 million in the nine months ended April 30, 2025 compared to $340.0 million in the same period in the prior year, which consisted of sales growth from acquisitions of 14.8%, which was partially offset by an organic sales decline of 1.9% and a decrease from foreign currency translation of 0.1%.

Organic sales in Europe declined in the mid-single digits in the three months ended April 30, 2025 and declined in the low-single digits in the nine months ended April 30, 2025 compared to the same periods in the prior year. Organic sales growth in the wire identification product line was more than offset by an organic sales decline in the product identification, safety and facility identification and people identification product lines during both the three and nine-month periods.

Organic sales in Australia declined in the mid-single digits in both the three and nine months ended April 30, 2025 compared to the same periods in the prior year. The organic sales decline was primarily driven by a decrease in volume in the safety and facility and wire identification product lines.

Europe & Australia segment profit decreased 10.5% to $17.5 million in the three months ended April 30, 2025 compared to $19.5 million in the same period in the prior year. Segment profit decreased 18.4% to $41.9 million in the nine months ended April 30, 2025 compared to $51.3 million in the same period in the prior year. As a percentage of net sales, segment profit decreased to 13.6% from 16.5% for the three-month period and segment profit decreased to 10.9% from 15.1% for the nine-month period ended April 30, 2025, compared to the same periods in the prior year. The decrease in segment profit and segment profit as a percentage of sales was primarily due to incremental amortization from acquired businesses, purchase accounting adjustments and reorganization costs in order to streamline our operating structure.

Liquidity and Capital Resources

The Company's cash balances are generated and held in numerous locations throughout the world. At April 30, 2025, 95% of the Company's cash and cash equivalents were held outside the United States. The Company's organic and inorganic growth has historically been funded by a combination of cash provided by operating activities and debt financing. The Company believes that its cash flow from operating activities and its borrowing capacity are sufficient to fund its anticipated requirements for working capital, capital expenditures, research and development, common stock repurchases, and dividend payments for the next 12 months. Although the Company believes these sources of cash are currently sufficient to fund domestic operations, annual cash needs could require repatriation of cash to the U.S. from foreign jurisdictions, which may result in additional tax payments.

Cash Flows

Cash and cash equivalents were $~~138~~152.52 million at ~~January~~April 3130, 2025, ana ~~increase~~decrease of $~~111~~98.70 million from July 31, 2024. The significant changes were as follows:

	Six months ended January 31,
	Nine months ended April 30,
(Dollars in thousands)	2025		2024
Net cash flow provided by (used in):
Operating activities	$	63122,~~000~~874	$	98171,~~351~~094
Investing activities	(~~151~~165,~~718~~079)		(6070,~~832~~331)
Financing activities	(2252,~~343~~077)		(4288,~~964~~989)
Effect of exchange rate changes on cash	(~~605~~3,682)		(2,~~227~~848)
Net decrease in cash and cash equivalents	$	(111,666)	$	(7,672)
Net (decrease) increase in cash and cash equivalents	$	(97,964)	$	8,926

Net cash provided by operating activities was $63122.09 million in the ~~six~~nine months ended ~~January~~April 3130, 2025, compared to $98171.41 million in the same period of the prior year. The decrease in cash provided by operating activities was primarily due to ~~increased~~changes ~~vendor~~in ~~payments~~working capital. Increased cash outflows related to ~~acquired~~inventory ~~businesses,~~were ~~increased~~primarily ~~inventory~~due ~~purchases~~to new product launches and the timing of facility moves during the nine months ended April 30, 2025. Additionally, higher ~~annual~~cash ~~incentive~~outflows ~~compensation~~related ~~payments~~to accounts payable in the current year were primarily driven by normalization of outstanding payables from acquired businesses.

Net cash used in investing activities was $151.7 million in the six months ended January 31, 2025, which primarily consisted of the acquisition of businesses of $137.3 million and capital expenditures of $14.4 million. Net cash used in investing activities was $60.8 million in the six months ended January 31, 2024, which consisted of capital expenditures including the purchase of a previously leased facility in Mexico and facility construction costs in Belgium.23

~~Net~~Table ~~cash~~of used in financing activities was $22.3 million in the six months ended January 31, 2025 compared to $43.0 million in the same period in the prior year. The decrease in cash used in financing activities was primarily due to a decline in share repurchases compared to the same period in the prior year.Contents

Net cash used in investing activities was $165.1 million in the nine months ended April 30, 2025, which primarily consisted of the acquisition of businesses of $147.2 million and capital expenditures of $18.7 million. Net cash used in investing activities was $70.3 million in the nine months ended April 30, 2024, which primarily consisted of capital expenditures including the purchase of a previously leased facility in Mexico and facility construction costs in Belgium.

Net cash used in financing activities was $52.1 million in the nine months ended April 30, 2025 compared to $89.0 million in the same period in the prior year. The decrease in cash used in financing activities was primarily due to a decline in share repurchases compared to the same period in the prior year.

Material Cash Requirements

Our material cash requirements for known contractual obligations include capital expenditures, borrowings on our credit agreement and lease obligations. We believe that net cash provided by operating activities will continue to be adequate to meet our liquidity and capital needs for these items over the next 12 months and in the long-term beyond the next 12 months. We also have cash requirements for purchase orders and contracts for the purchase of inventory and other goods and services, which are based on current and anticipated customer needs and are fulfilled by our suppliers within short time horizons. We do not have significant agreements for the purchase of inventory or other goods or services specifying minimum order quantities. In addition, we may have liabilities for uncertain tax positions, but we do not believe that the cash requirements to meet any of these liabilities will be material.

Credit Agreement

On August 1, 2019, the Company and certain of its subsidiaries entered into an unsecured $200 million multi-currency credit agreement with a group of five banks.

On November 14, 2022, the Company and certain of its subsidiaries entered into a second amendment to the credit agreement to, among other items, (a) increase the lending commitments by $100 million for total lending commitments of $300 million, (b) extend the final maturity date to November 14, 2027, (c) increase the interest rate on certain borrowings by 0.125%, and (d) increase the available amount under the credit agreement, at the Company's option and subject to certain conditions, from $300 million up to (i) an amount equal to the incremental borrowing necessary to bring the Company's consolidated net debt-to-EBITDA ratio as defined in the credit agreement to 2.5 to 1.0 plus (ii) $200 million.

On October 10, 2024, the Company and certain of its subsidiaries entered into a Third Amendment to Credit Agreement (“Amendment No. 3”) with a group of six banks, which amended the original credit agreement dated August 1, 2019. Amendment No. 3 amended the credit agreement to, among other things, change the applicable benchmark under the credit agreement for borrowings denominated in Canadian Dollars from the Canadian Dollar Offered Rate (“CDOR”) to the adjusted Term Canadian Overnight Repo Rate Average Rate (“CORRA”). Borrowings under Amendment No. 3 are unsecured and are guaranteed by certain of the Company's domestic subsidiaries.

23As of April 30, 2025, the outstanding balance on the Company's credit agreement was $102.8 million. The maximum amount outstanding on the credit agreement during the nine months ended April 30, 2025 was $144.8 million. As of April 30, 2025, the U.S. dollar-denominated borrowings of $42.0 million bear interest at 5.3%; the Euro-denominated borrowings of €44.0 million bear interest at 3.2%; and the British Pound-denominated borrowings of £8.0 million bear interest at 5.3%. The Company had letters of credit outstanding under the credit agreement of $2.0 million as of April 30, 2025, and there was $195.2 million available for future borrowing, which can be increased to $1,085.2 million at the Company's option, subject to certain conditions. The credit agreement has a final maturity date of November 14, 2027. As such, borrowings were classified as long-term on the condensed consolidated balance sheets.

Table of Contents

As of January 31, 2025, the outstanding balance on the Company's credit agreement was $87.7 million. The maximum amount outstanding on the credit agreement during the six months ended January 31, 2025 was $144.8 million. As of January 31, 2025, the U.S. dollar-denominated borrowings of $31.0 million bear interest at 5.3%; the Euro-denominated borrowings of €45.0 million bear interest at 3.8%; and the British Pound-denominated borrowings of £8.0 million bear interest at 5.6%. The Company had letters of credit outstanding under the credit agreement of $2.2 million as of January 31, 2025, and there was $210.1 million available for future borrowing, which can be increased to $1,095.1 million at the Company's option, subject to certain conditions. The credit agreement has a final maturity date of November 14, 2027. As such, borrowings were classified as long-term on the condensed consolidated balance sheets.

Covenant Compliance

The Company's credit agreement requires it to maintain certain financial covenants, including a ratio of debt to the trailing twelve months EBITDA, as defined in the debt agreements, of not more than a 3.5 to 1.0 ratio (leverage ratio) and the trailing twelve months EBITDA to interest expense of not less than a 3.0 to 1.0 ratio (interest expense coverage). As of ~~January~~April 3130, 2025, the Company was in compliance with these financial covenants, with a ratio of debt to EBITDA, as defined by the agreements, equal to 0.3 to 1.0 and the interest expense coverage ratio equal to 7371.5 to 1.0.

Forward-Looking Statements

In this quarterly report on Form 10-Q, statements that are not reported financial results or other historic information are “forward-looking statements.” These forward-looking statements relate to, among other things, the Company's future financial position, business strategy, targets, projected sales, costs, income, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations.

Table of Contents

The use of words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond Brady's control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For Brady, uncertainties arise from:

•Increased cost of ~~raw~~ materials, ~~and~~ labor, ~~as well as~~ material shortages and supply chain disruptions, including as a result of tariffs or other impacts of the global trade environment

•Decreased demand for the Company's products

•Ability to compete effectively or to successfully execute the Company's strategy

•Ability to develop technologically advanced products that meet customer demands

•Ability to identify, integrate, and grow acquired companies, and to manage contingent liabilities from divested businesses

•Difficulties in protecting websites, networks, and systems against security breaches and difficulties in preventing phishing attacks, social engineering or malicious break-ins

•Risks associated with the loss of key employees

•Global climate change and environmental regulations

•Litigation, including product liability claims

•Foreign currency fluctuations

•Changes in tax legislation and tax rates

•Potential write-offs of goodwill and other intangible assets

•Differing interests of voting and non-voting shareholders and changes in the regulatory and business environment around dual-class voting structures

•Numerous other matters of national, regional and global scale, including major public health crises and government responses thereto and those of a political, economic, business, competitive, and regulatory nature contained from time to time in Brady's U.S. Securities and Exchange Commission (“SEC”) filings, including, but not limited to, those factors listed in the “Risk Factors” section within Item 1A of Part I of Brady's Form 10-K for the year ended July 31, 2024.

These uncertainties may cause Brady's actual future results to be materially different than those expressed in its forward-looking statements. Brady does not undertake to update its forward-looking statements except as required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Refer to the Company’s annual report on Form 10-K for the year ended July 31, 2024. There has been no material change in this information since the 2024 Form 10-K.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Brady Corporation maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed by the Company in the reports filed by the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports the Company files under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company carried out an evaluation, under the supervision and with the participation of its management, including its President and Chief Executive Officer (the “Chief Executive Officer”) and its Chief Financial Officer, Chief Accounting Officer and Treasurer (the “Chief Financial Officer”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

There were no changes in the Company's internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the Company's most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information set forth in Note M, "Contingencies" included in this Quarterly Report on Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS

The Company’s business, results of operations, financial condition, and cash flows are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of Company’s Annual Report on Form 10-K for the year ended July 31, 2024. There have been no material changes from the risk factors set forth in the 2024 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The Company maintains a share repurchase program for the Company's Class A Nonvoting Common Stock. The program may be implemented by purchasing shares in the open market or in privately negotiated transactions, with repurchased shares available for use in connection with the Company's stock-based plans and for other corporate purposes.

On September 4, 2024, the Company's Board of Directors authorized an increase in the Company's share repurchase program, authorizing the repurchase of an additional $100.0 million of the Company's Class A Nonvoting Common Stock, which expanded upon the Company's prior authorization for a total authorized amount of $137.8 million. The share repurchase program may be implemented from time to time on the open market or in privately negotiated transactions and has no expiration date. As of ~~January~~April 3130, 2025, there was $~~137~~104.86 million worth of repurchase authority remaining pursuant to the existing share repurchase program.

The following table provides information with respect to the purchases by the Company of Class A Nonvoting Common Stock during the three months ended ~~January~~April 3130, 2025:

Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(Dollars in Thousands)
November 1, 2024 - November 30, 2024	—	$	—	—	$	137,788
February 1, 2025 - February 28, 2025	45,148	$	72.31	45,148	$	134,524
December 1, 2024 - December 31, 2024	—	—		—	137,788
March 1, 2025 - March 31, 2025	264,170	70.59		264,170	115,877
January 1, 2025 - January 31, 2025	—	—		—	137,788
April 1, 2025 - April 30, 2025	166,760	67.43		166,760	104,633
Total	—476,078	$	—69.64	—476,078	$	~~137~~104,~~788~~633

ITEM 5. OTHER INFORMATION

During the three months ended ~~January~~April 3130, 2025, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is identified in Item 408(a) of Regulation S-K.

Table of Contents

ITEM 6. EXHIBITS


Exhibit No.						Exhibit Description

31.1						Rule 13a-14(a)/15d-14(a) Certification of Russell R. Shaller

31.2						Rule 13a-14(a)/15d-14(a) Certification of Ann E. Thornton

32.1						Section 1350 Certification of Russell R. Shaller

32.2						Section 1350 Certification of Ann E. Thornton

101.INS						Inline XBRL Instance Document (The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.)

101.SCH						Inline XBRL Taxonomy Extension Schema Document

101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE						Inline XBRL Taxonomy Extension Presentation Label Linkbase Document

104						Cover Page Interactive Data File (Formatted as Inline XBRL contained in Exhibit 101)

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BRADY CORPORATION

Date: February 21, 2025

/s/ RUSSELL R. SHALLER

Date: May 16, 2025

/s/ RUSSELL R. SHALLER

Russell R. Shaller

President and Chief Executive Officer

(Principal Executive Officer)

Date: February 21, 2025

/s/ ANN E. THORNTON

Date: May 16, 2025

/s/ ANN E. THORNTON

Ann E. Thornton

Chief Financial Officer, Chief Accounting Officer and Treasurer

(Principal Financial Officer and Principal Accounting Officer)

Filing Compare · BRADY CORP